BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37309193)

  • 1. Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study.
    Kim JH; Jung HY; Yoo IK; Park SY; Kim JG; Sung JK; Jang JS; Cheon GJ; Kim KO; Kim TO; Lee ST; Cho KB; Chun HJ; Park JJ; Park MI; Jang JY; Jeon SW; Cho JW; Kang DH; Kim GH; Kim JJ; Kim SG; Kim N; Lee YC; Hong SJ; Kim HS; Lee S; Lee SW
    Gut Liver; 2024 Jan; 18(1):70-76. PubMed ID: 37309193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.
    Kim GH; Lee HL; Joo MK; Park HJ; Jung SW; Lee OJ; Kim H; Chun HJ; Lee ST; Kim JW; Jeon HH; Chung IK; Kim HS; Lee DH; Kim KO; Lim YJ; Park SJ; Cho SJ; Kim BW; Ko KH; Jeon SW; Kim JG; Sung IK; Kim TN; Sung JK; Park JJ
    Gut Liver; 2021 Nov; 15(6):841-850. PubMed ID: 33827990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
    Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of CKD-495 in acute and chronic gastritis: A Phase III superiority clinical trial.
    Seo SY; Lee ST; Kim SK; Chun HJ; Song GA; Lee DH; Kim JJ; Kim JI; Lee YC; Kim TN; Jee SR; Park SY; Kim JG; Park JJ; Kim SG; Park JM; Park JH; Park SJ; Lee OY
    Medicine (Baltimore); 2023 Dec; 102(49):e35926. PubMed ID: 38065906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
    Hu FL; Jia JC; Li YL; Yang GB
    J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Efficacy and Safety of DA-9601 versus Its New Formulation, DA-5204, in Patients with Gastritis: Phase III, Randomized, Double-Blind, Non-Inferiority Study.
    Choi YJ; Lee DH; Choi MG; Lee SJ; Kim SK; Song GA; Rhee PL; Jung HY; Kang DH; Lee YC; Lee SH; Choi SC; Shim KN; Seol SY; Moon JS; Shin YW; Kim HS; Lee ST; Cho JW; Choi EK; Lee OY; Jang JS
    J Korean Med Sci; 2017 Nov; 32(11):1807-1813. PubMed ID: 28960033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
    Hsu PI; Wu DC; Tsay FW; Cheng JS; Liu CP; Lai KH; Chen WC; Wang HM; Tsai TJ; Tsai KW; Kao SS
    Am J Gastroenterol; 2017 Feb; 112(2):282-289. PubMed ID: 27922030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective randomized controlled trial to compare the effects of omeprazole and famotidine in preventing delayed bleeding and promoting ulcer healing after endoscopic submucosal dissection.
    Tomita T; Kim Y; Yamasaki T; Okugawa T; Kondo T; Toyoshima F; Sakurai J; Tanaka J; Morita T; Oshima T; Fukui H; Hori K; Watari J; Matsumoto T; Miwa H
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1441-6. PubMed ID: 22497427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Famotidine in the treatment of gastritis.
    Miwa T; Miyoshi A
    Scand J Gastroenterol Suppl; 1987; 134():46-50. PubMed ID: 2889258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
    Nema H; Kato M
    World J Gastroenterol; 2010 Nov; 16(42):5342-6. PubMed ID: 21072898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.
    Taha AS; McCloskey C; Prasad R; Bezlyak V
    Lancet; 2009 Jul; 374(9684):119-25. PubMed ID: 19577798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.
    Kim GH; Choi MG; Kim JI; Lee ST; Chun HJ; Lee KL; Choi SC; Jang JY; Lee YC; Kim JG; Kim KB; Shim KN; Sohn CI; Kim SK; Kim SG; Jang JS; Kim N; Jung HY; Park H; Huh KC; Lee KJ; Hong SJ; Baek S; Han JJ; Lee OY
    Gut Liver; 2023 Nov; 17(6):884-893. PubMed ID: 36789577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Sigterman KE; Bonis P; Lau J; Numans ME
    Cochrane Database Syst Rev; 2010 Nov; (11):CD002095. PubMed ID: 21069670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
    Wong GLH; Lau LHS; Ching JYL; Tse YK; Ling RHY; Wong VWS; Chiu PWY; Lau JYW; Chan FKL
    Gut; 2020 Apr; 69(4):652-657. PubMed ID: 31229990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
    Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
    Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of adjuvant therapies by an H2-receptor antagonist and a proton pump inhibitor after endoscopic treatment in hemostatic management of bleeding gastroduodenal ulcers.
    Sakurada T; Kawashima J; Ariyama S; Kani K; Takabayashi H; Ohno S; Kato S; Yakabi K
    Dig Endosc; 2012 Mar; 24(2):93-9. PubMed ID: 22348833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events.
    Li X; Klompas M; Menchaca JT; Young JG
    Infect Control Hosp Epidemiol; 2020 Feb; 41(2):187-193. PubMed ID: 31818336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.